These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23832820)

  • 1. A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index.
    Bubis G; Hilly O; Bubis R; Halpern M; Schwartz A; Koren R; Rath-Wolfson L
    Pathol Oncol Res; 2013 Oct; 19(4):875-9. PubMed ID: 23832820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
    Varga Z; Cassoly E; Li Q; Oehlschlegel C; Tapia C; Lehr HA; Klingbiel D; Thürlimann B; Ruhstaller T
    PLoS One; 2015; 10(4):e0123435. PubMed ID: 25885288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.
    Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G
    Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer.
    Tramm T; Kyndi M; Sørensen FB; Overgaard J; Alsner J
    Acta Oncol; 2018 Jan; 57(1):102-106. PubMed ID: 29202620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.
    Debald M; Kaiser C; Abramian A; Schildhaus HU; Locher P; Wolfgarten M; Kuhn W; Braun M
    Anticancer Res; 2013 May; 33(5):1971-5. PubMed ID: 23645745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
    Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
    Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital quantification of KI-67 in breast cancer.
    Del Rosario Taco Sanchez M; Soler-Monsó T; Petit A; Azcarate J; Lasheras A; Artal C; Gil M; Falo C; Pla MJ; Matias-Guiu X
    Virchows Arch; 2019 Feb; 474(2):169-176. PubMed ID: 30465110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment.
    Orlando L; Viale G; Bria E; Lutrino ES; Sperduti I; Carbognin L; Schiavone P; Quaranta A; Fedele P; Caliolo C; Calvani N; Criscuolo M; Cinieri S
    Breast; 2016 Dec; 30():151-155. PubMed ID: 27750105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
    Moll R; Mitze M; Frixen UH; Birchmeier W
    Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
    Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
    J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 protein expression and proliferative activity in ductal breast carcinomas.
    Ioakim-Liossi A; Safioleas M; Karakitsos P; Athanassiadou P; Athanassiades P; Gogas J; Nakopoulou L
    Cytopathology; 2000 Aug; 11(4):255-61. PubMed ID: 10983725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears.
    Dalquen P; Baschiera B; Chaffard R; Dieterich H; Feichter GE; Krmer K; Torhorst J
    Acta Cytol; 1997; 41(2):229-37. PubMed ID: 9100748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast.
    Tan DS; Potts HW; Leong AC; Gillett CE; Skilton D; Harris WH; Liebmann RD; Hanby AM
    J Pathol; 1999 Sep; 189(1):20-7. PubMed ID: 10451483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.
    Varga Z; Diebold J; Dommann-Scherrer C; Frick H; Kaup D; Noske A; Obermann E; Ohlschlegel C; Padberg B; Rakozy C; Sancho Oliver S; Schobinger-Clement S; Schreiber-Facklam H; Singer G; Tapia C; Wagner U; Mastropasqua MG; Viale G; Lehr HA
    PLoS One; 2012; 7(5):e37379. PubMed ID: 22662150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.
    Kwon AY; Park HY; Hyeon J; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Cho SY; Cho EY
    PLoS One; 2019; 14(2):e0212309. PubMed ID: 30785924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters.
    Hemalatha A; Suresh TN; Kumar ML
    Indian J Cancer; 2013; 50(3):189-94. PubMed ID: 24061457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin and beta-catenin expression in breast medullary carcinomas.
    Charpin C; Bonnier P; Garcia S; Andrac L; Crebassa B; Dorel M; Lavaut MN; Allasia C
    Int J Oncol; 1999 Aug; 15(2):285-92. PubMed ID: 10402239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.